ResMed Inc. (NYSE:RMD) insider David Pendarvis sold 6,365 shares of the business’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $69.55, for a total value of $442,685.75. Following the completion of the sale, the insider now owns 84,261 shares of the company’s stock, valued at $5,860,352.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
David Pendarvis also recently made the following trade(s):
- On Monday, April 3rd, David Pendarvis sold 6,365 shares of ResMed stock. The stock was sold at an average price of $71.59, for a total value of $455,670.35.
Shares of ResMed Inc. (NYSE:RMD) traded up 1.33% during mid-day trading on Friday, hitting $68.40. The stock had a trading volume of 324,386 shares. The firm has a market cap of $9.70 billion, a PE ratio of 30.00 and a beta of 0.82. The stock has a 50 day moving average price of $69.27 and a 200 day moving average price of $66.40. ResMed Inc. has a 52 week low of $56.59 and a 52 week high of $73.46.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.01. ResMed had a return on equity of 22.82% and a net margin of 16.48%. The firm had revenue of $514.20 million for the quarter, compared to analysts’ expectations of $525.84 million. During the same period last year, the firm earned $0.68 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. Equities research analysts expect that ResMed Inc. will post $2.80 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, May 11th will be paid a dividend of $0.33 per share. The ex-dividend date of this dividend is Tuesday, May 9th. This represents a $1.32 dividend on an annualized basis and a dividend yield of 1.93%. ResMed’s dividend payout ratio (DPR) is currently 57.39%.
COPYRIGHT VIOLATION WARNING: This report was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/05/20/insider-selling-resmed-inc-rmd-insider-sells-442685-75-in-stock-updated.html.
A number of research firms have recently issued reports on RMD. Zacks Investment Research cut ResMed from a “hold” rating to a “sell” rating in a research report on Thursday, April 6th. JPMorgan Chase & Co. cut ResMed from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $72.00 to $71.00 in a research report on Thursday, April 20th. William Blair restated an “outperform” rating on shares of ResMed in a research report on Thursday, April 13th. Canaccord Genuity restated a “hold” rating and set a $59.00 price objective on shares of ResMed in a research report on Monday, February 6th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $61.00 price target on shares of ResMed in a research report on Tuesday, January 24th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $63.75.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI boosted its position in shares of ResMed by 0.3% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 5,238 shares of the medical equipment provider’s stock worth $377,000 after buying an additional 14 shares during the period. Morgan Dempsey Capital Management LLC boosted its stake in ResMed by 2.3% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,189 shares of the medical equipment provider’s stock valued at $158,000 after buying an additional 50 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in ResMed by 0.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 20,870 shares of the medical equipment provider’s stock valued at $1,295,000 after buying an additional 59 shares during the last quarter. Intrust Bank NA boosted its stake in ResMed by 1.0% in the first quarter. Intrust Bank NA now owns 7,101 shares of the medical equipment provider’s stock valued at $511,000 after buying an additional 73 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its stake in ResMed by 3.0% in the first quarter. Pacer Advisors Inc. now owns 2,699 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 79 shares during the last quarter. 62.51% of the stock is currently owned by hedge funds and other institutional investors.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.